Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
about
Does HAART efficacy translate to effectiveness? Evidence for a trial effectEfficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsLow dose versus high dose stavudine for treating people with HIV infectionEffectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIVEffectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIVTenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individualsLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesIn vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsRelationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Individualization of antiretroviral therapy--pharmacogenomic aspectEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trialHIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessRoutine HIV screening in France: clinical impact and cost-effectivenessScaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisBone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoStatistical methods in recent HIV noninferiority trials: reanalysis of 11 trialsEnrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, ThailandCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringMonitoring HIV viral load in resource limited settings: still a matter of debate?Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapyComparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort studyCost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling studyAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyThe Global Health Impact Index: Promoting Global HealthHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactGenotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone MarrowComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialEffectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisAssociation of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients.Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria.CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiImpact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
P2860
Q21135313-D19C218B-5F05-4D54-86C5-CE9680376F28Q21144607-0604DC99-8E9E-445F-9C85-D99D852BA9B1Q24186488-74DC62BD-704B-4C05-A84F-3C76E4D20F05Q24198027-3DF96827-52BF-4934-8044-00652A14C7B4Q24203685-50A79C76-5579-4099-BC79-1BC400DD1A67Q24234651-C4F18FB3-F0A7-452B-87F1-985346648356Q24597052-0872707E-8DC6-4F9C-8D98-C67D163E5DC5Q24674939-FB683E83-218D-4509-A754-133BABD96667Q27003431-4428CF6F-EFB9-426F-B434-184BADD8FAA8Q27015850-15299F6D-FF11-4F57-9E03-574902963D25Q28070574-9EE3BFB0-42CF-4B11-AE3C-A671662D32CBQ28081266-EAD920A2-066A-4FCD-9905-F8AD20809EB7Q28469218-68C1FE55-0AAB-4F3C-8568-1946C3AFEBFBQ28474086-4762F713-A9B7-45C9-9128-2E4E49F0C72FQ28475837-AF089FA6-2817-4F8C-8F32-76D993E5E9F8Q28476684-BB798FE7-6FC2-46CD-9642-2AEB0D4CB68FQ28476730-9F335D26-936E-4EA8-9D07-1E64215C0A13Q28476822-836CD2D6-6BF9-4087-B790-3445AE0A923FQ28477258-17E43FFF-1E2C-4385-8CCB-F1354B6A6580Q28482138-3E834407-F873-4697-A7A0-F28DCAB2E620Q28485511-33CFA34E-F6D0-4ED3-831D-90783B029648Q28487475-1D9BA9B3-07DF-4C1F-83F7-EB93A9ACB1E0Q28487986-D54F1CE2-32E5-4F73-95B5-94B97F99EF54Q28488157-E6A9AA09-1D29-4DF6-B567-4A4C41EA9B37Q28534423-C734F124-05F4-4BEB-91F8-ACE7F957EA9EQ28551476-6D80723C-8F1D-4F08-A4D6-2FDACA2B7A53Q28552455-2DEE106E-CE42-48D9-B064-5EFB7BB9A46FQ28553106-DF4E1896-B4CB-4E73-9360-72D164F3CBACQ28730855-13334DDF-BF32-4C71-92AB-29576FABE29CQ28742423-20746605-361D-44A8-A288-B5E60C044CF6Q30252384-82E606FE-7429-4926-9CE4-4BC9A7B8C3E4Q30380873-819DDE39-9589-4E06-94F3-EE7507E1058AQ30438405-2CAB6C71-9E79-4463-B8CE-D6F243B85A9AQ31028855-43442748-8607-4791-87AB-D59103480352Q33258171-278DE35A-428A-43DC-85D0-CC5768D4E0AAQ33265482-A2A187A5-F2A3-4647-BDF0-C1599E2170CBQ33565604-2BC819C0-3315-4704-B7AA-63153D5293D6Q33603586-A3709013-F79A-4747-AC7C-3C136A3F85D6Q33625367-341653AB-CC84-4DC0-8050-D8852C7D0F4AQ33710740-52ED2826-B327-4852-A8DC-B8589C864767
P2860
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@en
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@nl
type
label
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@en
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@nl
prefLabel
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@en
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@nl
P2093
P356
P1476
Tenofovir DF, emtricitabine, a ...... vudine, and efavirenz for HIV.
@en
P2093
Andrew K Cheng
Anton L Pozniak
Brian Gazzard
Damian McColl
Edwin DeJesus
Jeffrey Enejosa
Joel E Gallant
John J Toole
Rafael E Campo
P304
P356
10.1056/NEJMOA051871
P407
P577
2006-01-01T00:00:00Z